I-Acute Lymphoblastic Leukemia (T-ALL)-09

Umfundi waseyunivesithi ogama lakhe linguMengmeng waseYanjiao, eGuizhou, uthole ukwelashwa okuphumelelayo e-BIOOCUS Medical Group.

UMengmeng, owesifazane, oneminyaka engu-21 ubudala, wethulwa emtholampilo wethu wangaphandle ngomhlaka-22 Juni 2021, ekhathele njalo. Ukuhlolwa kwegazi okuvamile kubonise i-WBC 479×10^9/L. Ukuhlolwa okwengeziwe komnkantsha kwaqinisekisa i-acute lymphoblastic leukemia (i-T-cell subtype). Wenziwa imijikelezo emibili ye-chemotherapy, kodwa i-leukemia ayizange iphendule, kanti i-MRD (isifo esincane esisele) yayiku-56.01%, futhi wayene-central nervous system leukemia.

Ngo-Agasti 13, kwaqoqwa ama-lymphocyte e-autologous futhi kwanikezwa i-chemotherapy. Ngo-Agasti 30, uMengmeng wathola i-CD7 CAR-T cell infusion. Emasontweni amabili ngemuva kokufakwa, ukuhlolwa komnkantsha kwabonisa ukuphulukiswa okuphelele, ukungabi nandaba kwe-MRD, kanye nokulawulwa kwe-leukemia yesistimu yezinzwa ephakathi. Wabhekana nokusabela kwe-cytokine release syndrome (CRS) yebanga loku-1 ngaphandle kokusabela okubi kwesistimu yezinzwa ephakathi.